Akouos to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

BOSTON, Nov. 23, 2020 (GLOBE NEWSWIRE) — Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., CEO, President and co-founder, participated in a pre-recorded fireside chat that will be published today as part… Continue reading Akouos to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

Akouos to Present at Upcoming October Virtual Investor Conferences

BOSTON, Sept. 24, 2020 (GLOBE NEWSWIRE) — Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., CEO, President and co-founder, will present at two upcoming virtual investor conferences in October: Jefferies Gene Therapy/Editing Summit.… Continue reading Akouos to Present at Upcoming October Virtual Investor Conferences

Akouos Announces Expansion of Executive Team and Board of Directors

Alan Smith, Ph.D., Joins as Chief Technology Officer Saira Ramasastry Joins Board of Directors; Arthur Tzianabos, Ph.D., Role Expanded to Chairman BOSTON, Aug. 05, 2020 (GLOBE NEWSWIRE) — Akouos, Inc. (“Akouos”) (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the… Continue reading Akouos Announces Expansion of Executive Team and Board of Directors

Akouos to Present at BTIG Virtual Biotechnology Conference

BOSTON, Aug. 03, 2020 (GLOBE NEWSWIRE) — Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for people worldwide who live with disabling hearing loss, today announced that Manny Simons, Ph.D., M.B.A., CEO, President and co-founder, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference… Continue reading Akouos to Present at BTIG Virtual Biotechnology Conference

Akouos Announces Closing of Initial Public Offering

BOSTON, June 30, 2020 (GLOBE NEWSWIRE) — Akouos, Inc. (“Akouos”) (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss, today announced the closing of its initial public offering of 14,375,000 shares of… Continue reading Akouos Announces Closing of Initial Public Offering